Bryostatin-1 Fails to Ease Dementia in Moderate-to-Severe Alzheimer’s Patients in Phase 2 Trial

Bryostatin-1 Fails to Ease Dementia in Moderate-to-Severe Alzheimer’s Patients in Phase 2 Trial
An investigational Alzheimer's treatment called bryostatin-1 failed to meet its primary goal — lesser evidence of dementia in people with more severe disease — in a Phase 2 clinical trial, Neurotrope, the company developing the therapy, announced in a press release. Bryostatin-1 is a molecule that activates protein kinase C (PKC), which plays an important role in learning, memory, and maintaining the health of synapses — the places where neurons (nerve cells) come into contact with, and send signals to, each other. Prior studies — including another Phase 2 clinical trial — indicated that bryostatin-1 might be helpful in the clinical management of Alzheimer's disease. In this most recent trial (NCT03560245), 108 people with moderate to severe Alzheimer's disease were randomly assigned to intravenous (directly into the vein) treatment with either 20 mg of bryostatin-1 or a placebo, given seven times over the course of 12 weeks. The study's primary endpoint, or goal, was the change in total score for the Severe Impairment Battery (SIB) — a test designed to assess cognitive function in people with dementia who are unable to complete other psychological tests — from the study's start to week 13. Data found the average total SIB score increased by 1.3 points in the bryostatin-1-treated group, and it increased by 2.1 points in the placebo group.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *